Drug Profile
RU 105
Alternative Names: DE-105Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Santen Pharmaceutical
- Class Eye disorder therapies; Kinins; Nerve growth factors; Neuropeptides; Somatomedins
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Corneal disorders
Most Recent Events
- 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
- 13 Sep 2017 Discontinued - Phase-I for Corneal disorders in USA (Ophthalmic)
- 13 Sep 2017 Discontinued - Phase-II for Corneal disorders in Japan (Ophthalmic)